Tivicay Alternatives Compared
Tivicay (dolutegravir) | Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | Descovy (emtricitabine / tenofovir alafenamide) |
|
---|
Tivicay (dolutegravir) | Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | Descovy (emtricitabine / tenofovir alafenamide) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for HIV Infection. Tivicay may also be used for purposes not listed in this medication guide. |
Prescription only
Biktarvy is a combination tablet that contains three antiviral agents which may be used to treat HIV-1 in adults and children weighing more than 25kg (55lb). It is generally well-tolerated and the... View more |
Prescription only
Prescribed for HIV Infection, Pre-Exposure Prophylaxis of HIV. Descovy may also be used for purposes not listed in this medication guide. |
||||||||||||||||||||||||
More about Tivicay (dolutegravir) | More about Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | More about Descovy (emtricitabine / tenofovir alafenamide) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Tivicay has an average rating of 6.6 out of 10 from a total of 19 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 26% reported a negative effect. |
Biktarvy has an average rating of 7.2 out of 10 from a total of 226 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 19% reported a negative effect. |
Descovy has an average rating of 7.4 out of 10 from a total of 22 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 18% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Tivicay side effects |
View all Biktarvy side effects |
View all Descovy side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Tivicay prices |
View all Biktarvy prices |
View all Descovy prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other dolutegravir brands include: Tivicay PD |
N/A |
N/A |
||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
14 hours |
180 hours |
25.7 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 195 drugs are known to interact with Tivicay:
|
A total of 446 drugs are known to interact with Biktarvy:
|
A total of 249 drugs are known to interact with Descovy:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
August 12, 2013 |
February 07, 2018 |
April 04, 2016 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.